JOURNAL OF THE
NEUROLOGICAL SCIENCES

VOLUME 180, NOS. 1–2 1 NOVEMBER 2000

Special Issue

Advances in Amyotrophic Lateral Sclerosis

Papers from the 10th International Symposium on Amyotrophic Lateral Sclerosis/ Motor Neuron Disease held in Vancouver on November 15–17 November, 1999

CONTENTS

Preface
P.N. Leigh, W. Robberecht (UK and Belgium) 1

Six important themes in amyotrophic lateral sclerosis (ALS) research, 1999
L.P. Rowland (USA) 2

Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects?
J.-P. Julien, J.-M. Beaulieu (Canada) 7

Cognitive change in motor neurone disease/amyotrophic lateral sclerosis (MND/ALS)
D. Neary, J.S. Snowden, D.M.A. Mann (UK) 15

Novel drug development for amyotrophic lateral sclerosis
O. Hurko, F.S. Walsh (UK) 21

Ca^{2+}-permeable AMPA receptors and selective vulnerability of motor neurons
L. Van Den Bosch, W. Vandenberghe, H. Klaassen, E. Van Houtte, W. Robberecht (Belgium) 29

Ultrastructural analysis of spinal motoneurones from mice treated with IgG from ALS patients, healthy individuals, or disease controls
A.H. Pullen, P. Humphreys (UK) 35

Interneuronal survival and calbindin-D28K expression following motoneuron degeneration
S.M.C. Lim, R.J. Guiloff, R. Navarrete (UK) 46

Beneficial effect of ginseng root in SOD-1 (G93A) transgenic mice
F. Jiang, S. DeSilva, J. Turnbull (Canada) 52

Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (*pmn*)
P. Kennel, F. Revah, G.A. Bohme, R. Bejuit, P. Gallix, J.-M. Stutzmann, A. Imperato, J. Pratt (France) 55

Decreased striatal dopamine D2 receptor binding in amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA): D2 receptor down-regulation versus striatal cell degeneration
O.J.M. Vogels, J. Veltman, W.J.G. Oyen, M.W.I.M. Horstink (The Netherlands) 62

The split hand in ALS has a cortical basis
M. Weber, A. Eisen, H. Stewart, N. Hirota (Canada) 66

Temporal dispersion of cortically evoked single motor unit potentials in ALS
N. Hirota, M. Weber, A. Eisen (Canada) 71

Diagnostic delay in amyotrophic lateral sclerosis: what scope for improvement?
E. Househam, M. Swash (UK) 76

German open label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS)
D. Pongratz, B. Neundörfer, W. Fischer (Germany) 82

Development of a patient-specific dyspnoea questionnaire in motor neurone disease (MND): the MND dyspnoea rating scale (MDRS)
C.F. Dougan, C.O. Connell, E. Thornton, C.A. Young (UK) 86

The amyotrophic lateral sclerosis assessment questionnaire (ALSAQ-40): tests of data quality, score reliability and response rate in a survey of patients
C. Jenkinson, G. Levvy, R. Fitzpatrick, A. Garratt (UK) 94

Attributions, strain and depression in carers of partners with MND: a preliminary investigation
L.H. Goldstein, M. Adamson, T. Barby, K. Down, P.N. Leigh (UK) 101

A neuropsychological investigation of dementia in motor neurone disease (MND)
F.P. Barson, G.J. Kinsella, B. Ong, S.E. Mathers (Australia) 107

Calendar of Events 114

Instructions to Authors 116

Cited in: Biological Abstracts (BIOSIS) – Chemical Abstracts – Current Awareness in Biological Sciences (CABS) – Current Contents/Life Sciences – EMBASE – Index Medicus – Medline – Neurosciences Citation Index – Pascal et Francis (INST-CNRS) – PubMed – Reference Update (via Research Information Systems) – Research Alert – Science Citation Index – Science Citation Index – Expanded (SciSearch or ISI Web of Science)